AKTX
AKTX clinical trials: Akari Therapeutics Plc
Every trial on ClinicalTrials.gov where Akari Therapeutics Plc is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 8
- Trials linked
- 8
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
AKTX on the catalyst calendar · AKTX registry changes
- Primary completion May 15, 2024ActualPhase 3NCT04784455Nomacopan (rVA576) in Transplant Associated Thrombotic MicroangiopathyAKARI Therapeutics · Thrombotic MicroangiopathiesTerminatedAKTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 12, 2020ActualPhase 2NCT04035733rVA576 in Adult Mild to Moderate Bullous Pemphigoid SubjectsAKARI Therapeutics · Bullous Pemphigoid (BP)CompletedAKTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 15, 2018ActualPhase 2NCT03427060Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 PolymorphismsAKARI Therapeutics · Paroxysmal Nocturnal Hemoglobinuria (PNH)CompletedAKTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 1, 2022ActualPhase 3NCT05061771Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)AKARI Therapeutics · Bullous PemphigoidWithdrawnAKTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 30, 2020ActualPhase 1/Phase 2NCT04037891Topical rVA576 for Treatment of Atopic KeratoconjunctivitisAKARI Therapeutics · Keratoconjunctivitis, AtopicTerminatedAKTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 29, 2020ActualPhase 3NCT03829449rVA576 (Coversin) Long Term Safety and Efficacy Surveillance StudyAKARI Therapeutics · Paroxysmal Nocturnal HemoglobinuriaTerminatedAKTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 3, 2020ActualPhase 3NCT03588026Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576AKARI Therapeutics · Paroxysmal Nocturnal Hemoglobinuria (PNH)CompletedAKTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 20, 2018ActualPhase 2NCT02591862Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH)AKARI Therapeutics · Paroxysmal Nocturnal Haemoglobinuria (PNH)CompletedAKTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 8 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner